stockrowThermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.
- Revenue
- +9.13%
- EPS
- +8.64%
- Free cash flow
- +15.0%
- Total debt
- +22.8%
Quarter to September 2026, against a year earlier
Follow TMO
Alert me
Thermo Fisher Scientific Inc. (TMO) EPS (diluted)
Thermo Fisher Scientific Inc.'s EPS (diluted) for fiscal 2025 was $17.74, up 7.32% from $16.53 in fiscal 2024. Over the twelve months to 30 September 2026 it was $18.96. Over the past ten years it has ranged from $4.92 (fiscal 2015) to $19.46 (fiscal 2021); the current reading is higher than 91% of that period. Thermo Fisher Scientific Inc. ranks 2nd of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $17.74 | 7.32% |
| FY2024 | $16.53 | 6.99% |
| FY2023 | $15.45 | (12.37%) |
| FY2022 | $17.63 | (9.40%) |
| FY2021 | $19.46 | 21.93% |
| FY2020 | $15.96 | 74.05% |
| FY2019 | $9.17 | 26.66% |
| FY2018 | $7.24 | 29.52% |
| FY2017 | $5.59 | 9.82% |
| FY2016 | $5.09 | 3.46% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $4.64 | (0.85%) |
| Jun 2026 | $4.68 | 5.64% |
| Mar 2026 | $4.43 | (14.97%) |
| Dec 2025 | $5.21 | 22.01% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| TMO Thermo Fisher Scientific Inc. | $18.96 |
| IDXX IDEXX Laboratories, Inc. compare | $14.83 |
| IQV IQVIA Holdings Inc. compare | $8.24 |
| DHR Danaher Corporation compare | $6.11 |
| ILMN Illumina, Inc. compare | $5.81 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation compare | $2.33 |
| NTRA Natera, Inc. compare | −$1.14 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TMO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement